Ingredient · Evidence grade C

EstroG-100 for menopause: evidence, studies and safety

Last updated · 4 studies summarized

C Short answer: EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products.

Key facts

Evidence gradeC C
Use studiedmenopausal symptoms incl. hot flashes
Trials3 placebo RCTs (Chang 2012 n=64; Farzaneh 2024 n=120/70 analyzed; Snigdha 2025 n=80 combo with GABA)
Participants~264 randomized
What reviews concludeNo independent meta-analysis found.
The Menopause Society (2023)Not specifically assessed (falls under 'supplements/herbal remedies – not recommended').
Also known asEstroG-100, Estro G-100

Grades: A strong · B moderate · C limited · D none or negative. How we grade.

Every study we reviewed

Each summary gives who took part, the dose, how long, the result compared with placebo or control, and who paid for it.

  • The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.

    Chang A, Kwak BY, Yi K et al. · Phytother Res 2012 · EstroG-100

    64 US women took EstroG-100 (a Korean 3-herb blend) or placebo for 12 weeks. Overall symptom scores, including hot flashes and vaginal dryness, improved much more than with placebo. It is one small study and has not been widely repeated.

    Who
    64 women (US, multi-ethnic)
    Dose
    EstroG-100 daily
    Duration
    12 weeks
    Result
    Kupperman Index 29.5→11.3 vs 29.2→23.7 placebo (P<.01); vaginal dryness improved.
    Funding
    Not stated in abstract (ingredient maker Naturalendo Tech is the developer; not verified). Funding not stated

    PubMed · Full text (DOI)

  • Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.

    Farzaneh F, Fallah G, Khalili-Chelik A et al. · Explore (NY) 2024 · EstroG-100

    In Iran, postmenopausal women took EstroG-100 or placebo; only 70 of 120 were analyzed. By week 6 the EstroG-100 group reported fewer hot flashes. The high drop-out rate weakens the result.

    Who
    120 randomized, 70 analyzed (Iran)
    Dose
    EstroG-100 daily
    Duration
    12 weeks (results reported at weeks 3–6)
    Result
    Fewer mild, moderate and severe hot flashes vs control at week 6 (P<.001).
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

  • Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.

    Snigdha S, Lau E, Ademola J et al. · Menopause 2025 · EstroG-100

    80 women took OLLY's EstroG-100 + GABA product or placebo for 5 weeks. Hot flashes, sleep and mood improved more than placebo. The study was run by the company that sells the product.

    Who
    80 women
    Dose
    EstroG-100 514 mg + GABA 50 mg (OLLY Mellow Menopause)
    Duration
    5 weeks
    Result
    Hot-flash intensity and number fell vs placebo from days 1–2; sleep, mood and sexual function improved at later time points.
    Funding
    Authors are employees of OLLY PBC, the product's manufacturer. Industry-linked

    PubMed · Full text (DOI)

  • Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97.

    EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Turck D, Bresson JL et al. · EFSA J 2017 · EstroG-100

    Europe's food-safety agency approved EstroG-100 only up to 175 mg a day – about a third of the dose used in many US products and trials – because of limited long-term safety data.

    Who
    n/a (EU safety opinion)
    Dose
    max 175 mg/day judged safe
    Duration
    n/a
    Result
    EFSA considered EstroG-100 safe at 175 mg/day in postmenopausal women (lower than the 514 mg/day proposed) because of liver/blood findings in animal studies and limited human data.
    Funding
    EFSA (independent EU regulator). Independent / academic

    PubMed · Full text (DOI)

Safety

EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS).

Ranked products that contain it

Ranked products containing EstroG-100, by our score.
ProductAmount per dayScore$/day
Thorne Perimenopause CompleteEstroG-100 botanical blend: 514 mg64.6$1.73
OLLY Mellow MenopauseEstroG-100 proprietary extract: 514 mg50.4$1.00

FAQ

Does EstroG-100 help with menopause symptoms?

EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products. Our evidence grade is C. No independent meta-analysis found.

Does The Menopause Society recommend EstroG-100?

Not specifically assessed (falls under 'supplements/herbal remedies – not recommended'). The 2023 nonhormone statement recommends no dietary supplement for hot flashes; talk to a clinician about hormone therapy and prescription options.

Is EstroG-100 safe?

EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS). Supplements are not FDA-approved before sale; ask a clinician or pharmacist, especially if you take medication.

Sources

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.